Valuation: MediWound Ltd.

Market Cap 171M 146M 137M 125M 235M 16.32B 238M 1.61B 630M 8.2B 640M 626M 27.11B P/E 2026 *
-6.02x
P/E 2027 * -6.01x
Enterprise Value 171M 146M 137M 125M 235M 16.32B 238M 1.61B 630M 8.2B 640M 626M 27.11B EV / Sales 2026 *
7.2x
EV / Sales 2027 * 5.36x
Free-Float
84.04%
Yield 2026 *
-
Yield 2027 * -
1 day+0.72%
1 week-2.58%
Current month-6.44%
1 month-7.49%
3 months-21.56%
6 months-26.08%
Current year-28.44%
1 week 13.06
Extreme 13.06
13.92
1 month 13.06
Extreme 13.06
14.87
Current year 13.06
Extreme 13.06
19.7
1 year 13.06
Extreme 13.06
20.3
3 years 7.1
Extreme 7.1
24
5 years 7.1
Extreme 7.1
28.07
10 years 7.1
Extreme 7.1
60.06
Manager TitleAgeSince
Chief Executive Officer 52 2022-06-29
Director of Finance/CFO 54 2023-05-13
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 72 2017-05-17
Chairman 69 2017-10-24
Director/Board Member 68 2020-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+0.72%-2.58%-24.04%+46.94% 171M
+0.90%+3.80%+39.43%-1.22% 83.28B
+8.86%+129.20%+453.51%+30.65% 57.92B
-1.69%+23.30%-25.53%-36.93% 57.77B
-1.46%+0.19%-0.81%+29.66% 51.75B
+1.74%+4.43%+11.41%+172.02% 49.35B
+1.13%+3.31%+55.82%-18.22% 32.03B
+0.46%+6.37%+47.71%+96.99% 25.91B
+1.19%+9.17%+3.12%+228.73% 22.74B
-0.30%+4.45%+60.84%+124.17% 16.87B
Average +0.30%+18.16%+62.15%+67.28% 39.78B
Weighted average by Cap. +0.19%+24.96%+82.24%+47.25%

Financials

2026 *2027 *
Net sales 23.67M 20.28M 18.98M 17.37M 32.6M 2.27B 33.03M 224M 87.43M 1.14B 88.9M 86.96M 3.76B 31.81M 27.24M 25.49M 23.34M 43.79M 3.04B 44.37M 301M 117M 1.53B 119M 117M 5.06B
Net income -29.11M -24.94M -23.33M -21.36M -40.08M -2.79B -40.61M -276M -107M -1.4B -109M -107M -4.63B -31.82M -27.26M -25.5M -23.34M -43.81M -3.04B -44.39M -301M -117M -1.53B -119M -117M -5.06B
Net Debt - -
Logo MediWound Ltd.
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Employees
121
Date Price Change Volume
26-08-21 US$13.21 +0.72% 79,832
26-08-20 US$13.12 -3.50% 81,387
26-08-19 US$13.59 -0.37% 53,611
26-08-18 US$13.64 +1.87% 56,423
26-08-17 US$13.39 -1.25% 74,006
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.21USD
Average target price
29.83USD
Spread / Average Target
+125.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDWD Stock